CompletedPhase 1

Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension

United States20 participantsStarted 2008-09

Plain-language summary

The purpose of this this study is to investigate the clinical utility of renal denervation in the treatment of ESRD patients with refractory hypertension.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Systolic blood pressure of 160 mmHg or greater * On 3 or more antihypertensive medications * On dialysis for more than 6 months Exclusion Criteria: * Renal artery abnormalities * Known secondary hypertension attributable to a cause other than sleep apnea * MI, angina, CVA within 6 months * Others

What they're measuring

Safety - complications associated with delivery and/or use of the Ardian Catheter, adverse renal events, electrolyte disturbances, hemodynamic events.

Timeframe: Through 1 year

Trial details

NCT IDNCT00753116

SponsorMedtronic Vascular

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-12

View on ClinicalTrials.gov More Kidney Failure, Chronic trials